Online Program

316895
Infrastructure and implementation for policy, systems, and environmental change: Comparing demonstration and traditional comprehensive cancer control programs


Wednesday, November 4, 2015

Marilyn Sitaker, MPH, Battelle Memorial Institute, Seattle, WA
John Rose, Ph.D., Health and Analytics, Battelle Memorial Institute, Arlington, VA
Angela Moore, MPH, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA
Julie Townsend, MS, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Chamblee, GA
Monique Young, MPH, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA
Gary Chovnick, DrPH, MPH, Health and Analytics, Battelle Memorial Institute, Seattle, WA
Elizabeth Rohan, PhD, MSW, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA
Background: Policy, system and environmental (PSE) change strategies may greatly facilitate efforts to address disease burden through primary, secondary, and tertiary prevention. CDC invested in this approach by providing demonstration program funding to 13 of the 65 grantees funded through the National Comprehensive Cancer Control Program (NCCCP), to determine whether this approach would enhance the processes used to develop and implement PSE change strategies.

Methods: As part of a comprehensive, longitudinal, mixed-methods evaluation, we implemented the first of two web surveys of program directors, comparing demonstration programs with traditional NCCCP programs, to determine the impact of program funding on grantees’ capacity, infrastructure, and implementation of PSE change strategies. Analysis was primarily descriptive, employing bivariate statistical methods with tables and graphs for display and summarization.

Results: Demonstration programs were more likely than traditional programs to report high staff competency for PSE work, and to have a Workgroup with skilled members that lead PSE change efforts. Demonstration programs found National Partners’, a cancer control collaborative,  trainings on developing key messages most helpful in building capacity, while traditional programs preferred interaction with other grantees. Demonstration programs’ Workgroups were more likely to address decision makers’ lack of awareness or knowledge, and to identify opponents, try to understand their position, and look for ways to manage opposition to PSE change.

Conclusions: Survey results show enhanced capacity among demonstration program staff and partners to plan and implement PSE change strategies, providing valuable insights into methods used to engage stakeholders who are critical to the implementation process.

Learning Areas:

Conduct evaluation related to programs, research, and other areas of practice
Implementation of health education strategies, interventions and programs
Public health or related public policy

Learning Objectives:
Describe differences between a PSE-focused demonstration project and a traditional cancer prevention and control program in infrastructure, capacity building, and implementation of primary, secondary, and tertiary prevention strategies for cancer. Compare the methods used by a PSE-focused demonstration project and a traditional cancer prevention and control program for working with stakeholders and decision makers to implement policy, system and environmental change strategies. Describe the demonstration program and the evaluation of its effectiveness.

Keyword(s): Policy/Policy Development, Community-Based Partnership & Collaboration

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I am qualified to present because I have been part of the CDC-Battelle 1017 mixed methods evaluation team since its inception in 2011. I developed the Program Director Survey, oversaw its administration and analysis, and wrote the summary report.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.